December 2000
Worldwide Biotech;Dec2000, Vol. 12 Issue 12, p4
Trade Publication
Deals with the agreement between Human Genome Sciences Inc. and Aventis Behring L.L.C. to co-develop and jointly market an Aventis Behring plasma protein product. Reports that Human Genome Sciences, Inc. and Aventis Behring L.L.C. have signed a development and commercialization agreement to co-develop and jointly market an Aventis Behring blood plasma protein product. Possible product advantages of linking a therapeutic plasma protein with albumin; Contact information.


Related Articles

  • Human Genome Sciences Forms Biotech Deals. Papanikolaw, Jim // Chemical Market Reporter;03/06/2000, Vol. 257 Issue 10, p22 

    Reports on the alliances made by Human Genome Sciences Inc. to enhance its ability to study genes and their expressions. Companies involved in the deals; Expected results of the collaboration; Comments from William A. Haseltine, chairman of the company.

  • HGS Partners with Hospira and Eden Biodesign to Make Use of Excess Capacity.  // BioPharm International;Oct2008, Vol. 21 Issue 10, p17 

    The article reports on the manufacturing partnerships between Human Genome Sciences Inc. (HGS), Hospira Inc. and the UK-based Eden Biodesign Ltd. The agreement will allow HGS to profit from its excess biomanufacturing capacity. The deal with Hispora will allow HGS to carry out manufacturing...

  • Interferon Filing Done as HGS Revs Benlysta.  // Bioworld Week;12/7/2009, Vol. 17 Issue 49, p2 

    The article reports that Human Genome Sciences Inc. (HGS), has filed the biologics license application (BLA) for hepatitis C drug Zalbin, instead of highly demanding BLA for lupus drug Benlysta. Various examples of the studies related to the quantity of Zalbin to be given to the patients, is...

  • Transatlantic biotech deal. Dorey, Emma // Nature Biotechnology;Apr2000, Vol. 18 Issue 4, p366 

    Reports on the agreement between Cambridge, England-based Cambridge Antibody Technology Ltd. (CTA) and Rockville, Maryland-based genomics company Human Genome Sciences Inc. to turn human genome data into human antibody-based therapies and diagnosis. Terms of the deal; Rights of CTA related to...

  • Partnering Your Way to M&A? Keep Cash Balance, Options. Boggs, Jennifer // BioWorld Today;2/13/2013, Vol. 24 Issue 30, p1 

    The article offers information on the structures that can prevent or encourage the transaction of mergers and acquisitions on biotechnology industries. Former chief executive office (CEO) Thomas Watkins of Human Genome Sciences Inc. (HGS) states that the reason of their partnership with...

  • DIGEST.  // Chemical Week;6/23/2004, Vol. 166 Issue 21, p35 

    Presents news briefs related to the pharmaceuticals and chemical industry as of June 23, 2004. Alliance formed by Hovione with privately owned generic drug company CyDex; Contract awarded to Diosynth and Human Genome Sciences to develop a process for the manufacture of clinical quantities of an...

  • SmithKline backs sequencing company. Gershon, Diane // Nature;6/3/1993, Vol. 363 Issue 6428, p387 

    Reports that Human Genome Sciences Inc. (HGS) of Rockville, Maryland, has formed a strategic alliance with the Anglo-American pharmaceutical company SmithKline Beecham (SKB). Details of the agreement reached between the two firms; Additional information.

  • Human Genome Sciences builds new $45 m plant.  // Chemical Market Reporter;10/06/97, Vol. 252 Issue 14, p14 

    Reports on Human Genome Sciences Inc.'s construction of a manufacturing and process development plant in Montgomery County, Maryland.

  • Court voids HGS gene patent. Francisco, Michael // Nature Biotechnology;Apr2010, Vol. 28 Issue 4, p300 

    The article reports that a British Court of Appeal has terminated the patent held by Human Genome Sciences (HGS) for the neutrokine-α gene sequence in April 2010.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics